FOLH1 and neoplasm: Translating the in vitro findings to an in vivo therapy study, a single fraction of EBRT delivering a clinically relevant dose of 2 Gy followed by 40 MBq of PSMA-RLT resulted in a long-lasting stabilization of tumor growth.